Pharma BD Deal Intelligence

CORE Biomedicine, Inc. / Eisai Co., Ltd.

2026 · Licensing/Option · Complete

CORE Biomedicine announced on 2026-07-28 an exclusive licensing agreement with Eisai Co., Ltd. granting CORE exclusive global rights to develop and commercialize multiple preclinical oncology programs originally discovered through Eisai research. The programs target molecular drivers across distinct targets and biological pathways, aligned to CORE's lineage-biology precision-medicine strategy. CORE Biomedicine was established by oncology drug development leaders specifically to advance these programs and operates in the United States, Japan and China. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals